Merit Medical Systems, Inc. Stock News

SOUTH JORDAN, Utah, May 20, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C. (“Biolife”) in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is headquartered in Sarasota, Florida, manufactures unique patented hemostat...

SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's ...

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q1 2025 Results Conference Call April 24, 2025 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Raul Parra - Chief Financial Officer and Treasurer Brian Lloyd - Chief Legal Officer & Corporate Secretary Conference Call Participants Jason Bednar - Piper Sandler Steve Lichtman - Oppenheimer Robbie Marcus - J...

Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia

SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (T...

Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms. Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.

SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International . Twelve-month results from the randomized arm of the WAV...